Location History:
- Carlsbad, CA (US) (2012)
- Cardiff, CA (US) (2013)
Company Filing History:
2 out of 164 
2 out of 38 
Years Active: 2012-2013
Title: The Innovations of Frederick Charles Bancroft
Introduction
Frederick Charles Bancroft is a notable inventor based in Cardiff, California. He has made significant contributions to the field of biotechnology, particularly in the development of bioassays for GLP-1 receptor agonists. With a total of two patents to his name, Bancroft's work has implications for diabetes treatment and research.
Latest Patents
Bancroft's latest patents focus on GLP-1 receptor agonist bioassays. These patents provide cell-based bioassays for measuring the activity of test compounds, such as GLP-1 receptor agonist compounds. The bioassays are designed to quantitatively determine cAMP generated in samples containing these compounds, including exenatide. The assays utilize 6-23 (clone 6) cells that have GLP-1 receptors, allowing for a correlation between the amount of cAMP generated and the agonist activity of the compounds. Suitable methods for these bioassays include enzyme-linked immunosorbent assays and homogeneous time-resolved fluorescence assays.
Career Highlights
Throughout his career, Bancroft has worked with prominent companies in the pharmaceutical industry. He has been associated with Amylin Pharmaceuticals, Inc. and AstraZeneca Pharmaceuticals LP. His experience in these organizations has contributed to his expertise in developing innovative solutions in the field of biotechnology.
Collaborations